Clinical Trial Update: Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for the Chikungunya vaccine V184 in adults previously exposed to the virus; study completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chikungunya Virus Infection

Drugs mentioned

• V184

Snippet

Sponsor: Themis Bioscience GmbH | Conditions: Chikungunya Virus Infection | Phase 2 | Status: COMPLETED | Results posted: 2022-05-16